AbCellera Biologics Target Price

Analysts' average 12-month price target for AbCellera Biologics is $18.

Get informed when a big investor buys or sells

+ Follow

Share Price

$12.5

Average Target Price

$18.20

45.6% upside

5 analysts in the last 4 months

High: $30 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-30	JefferiesRoger Song	$21	68% upside
2026-10-11	UBS	$18	44% upside
2026-09-24	Goldman Sachs	$13	4% upside
2026-08-11	Truist Financial	$30	140% upside
2026-08-06	Stifel Nicolaus	$9	28% downside
2026-05-12	Stifel Nicolaus	$8	36% downside
2026-05-05	Cantor Fitzgerald	$7	44% downside
2024-11-05	BMO CapitalGary Nachman	$5	60% downside
2024-08-23	KeyBancScott Schoenhaus	$5	60% downside
2024-05-08	KeyBancScott Schoenhaus	$7	44% downside
2023-01-06	Leerink Partners	$18	44% upside
2022-12-15	Goldman SachsAndrea Tan	$30	140% upside
2022-11-16	Truist Financial	$29	132% upside
2022-08-10	Credit Suisse	$34	172% upside

AbCellera Biologics (ABCL) FAQ

AbCellera Biologics (ABCL) currently reports a target price of $18. Use the charts on this page to explore AbCellera Biologics's target price history and peer comparisons.

Analysts' average 12-month price target for AbCellera Biologics is $18, about 45.6% upside from the current share price of $12.5. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $18, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.